NCT06617286Not yet recruitingPhase 1/2
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
MAC-CAR: A Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 9 Sept 2024
- Start date
- 1 Dec 2026
- Primary completion date
- 31 Dec 2039
- Lead sponsor
- New York Medical College
- Diseases
- Childhood cancers
- NCT number
- NCT06617286
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 21
- From 1 Dec 2026 to the primary completion date, 31 Dec 2039
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- not meeting the inclusion criteria
Who the study is looking for
- Age between ≥ 6 and ≤ 29.99 years at the time of consent.
- Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
- Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:
- Induction failure Progressive disease Disease relapse (1st, 2nd or 3rd)
- Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.
- Risk Factors: Patient must meet 2 or more of the established risk factors:
- Performance score (Karnofsky/Lansky) \<;90% Time from diagnosis to first relapse of \<1 year Extra nodal involvement at the time of relapse/progression High baseline metabolic tumor volume (MTV, \>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction
Age in the registry: 6 years to 29 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New York Medical College Coordinator of this site? Confirm its status | Valhalla | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.